Impact on Human Health of Salmonella spp. and Their Lipopolysaccharides: Possible Therapeutic Role and Asymptomatic Presence Consequences.

Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067 (Electronic) Linking ISSN: 14220067 NLM ISO Abbreviation: Int J Mol Sci Subsets: MEDLINE

Original Publication: Basel, Switzerland : MDPI, [2000-

Lipopolysaccharides* ; Salmonella* ; Salmonella Infections*/microbiology ; Salmonella Infections*/drug therapy ; Salmonella Infections*/immunology; Humans ; Animals

Epidemiologically, one of the most important concerns associated with introducing Salmonella spp. into the environment and food chain is the presence of asymptomatic carriers. The oncogenic and oncolytic activity of Salmonella and their lipopolysaccharides (LPSs) is important and research on this topic is needed. Even a single asymptomatic dose of the S. Enteritidis LPS (a dose that has not caused any symptoms of illness) in in vivo studies induces the dysregulation of selected cells and bioactive substances of the nervous, immune, and endocrine systems. LPSs from different species, and even LPSs derived from different serotypes of one species, can define different biological activities. The activity of low doses of LPSs derived from three different Salmonella serotypes ( S . Enteritidis, S. Typhimurium, and S. Minnesota) affects the neurochemistry of neurons differently in in vitro studies. Studies on lipopolysaccharides from different Salmonella serotypes do not consider the diversity of their activity. The presence of an LPS from S . Enteritidis in the body, even in amounts that do not induce any symptoms of illness, may lead to unknown long-term consequences associated with its action on the cells and biologically active substances of the human body. These conclusions should be important for both research strategies and the pharmaceutical industry &.

PLoS One. 2009;4(5):e5482. (PMID: 19424495)
Toxicol Res (Camb). 2017 Oct 26;7(1):73-83. (PMID: 30090564)
Neurology. 2016 Nov 29;87(22):2324-2332. (PMID: 27784770)
Virulence. 2014 Jan 1;5(1):213-8. (PMID: 24193365)
FEMS Microbiol Rev. 2016 Jul;40(4):480-93. (PMID: 27075488)
Infect Immun. 2019 Dec 17;88(1):. (PMID: 31611279)
Nutr Diabetes. 2013 Aug 26;3:e83. (PMID: 23978817)
Neurosci Biobehav Rev. 2020 Aug;115:15-24. (PMID: 32433924)
Acta Diabetol. 2015 Apr;52(2):395-404. (PMID: 25326898)
Front Microbiol. 2017 Apr 25;8:684. (PMID: 28487676)
Cell Insight. 2023 Oct 11;2(5):100125. (PMID: 37886657)
Cell Host Microbe. 2024 Jan 10;32(1):79-92.e7. (PMID: 38211565)
Int J Mol Sci. 2023 May 07;24(9):. (PMID: 37176105)
Curr Issues Mol Biol. 2024 Jul 14;46(7):7447-7472. (PMID: 39057083)
Cell Death Discov. 2023 Aug 28;9(1):318. (PMID: 37640735)
Acta Biochim Biophys Sin (Shanghai). 2023 Feb 25;55(3):331-342. (PMID: 36786073)
Pharmaceutics. 2023 Aug 27;15(9):. (PMID: 37765183)
Cell Rep Med. 2022 Dec 20;3(12):100852. (PMID: 36543099)
Toxins (Basel). 2019 Feb 02;11(2):. (PMID: 30717384)
Infect Immun. 2014 Nov;82(11):4553-62. (PMID: 25135686)
Front Microbiol. 2022 Jun 29;13:914575. (PMID: 35847095)
Int J Mol Sci. 2020 Jun 13;21(12):. (PMID: 32545766)
Front Microbiol. 2021 Dec 23;12:774490. (PMID: 35003007)
Cell. 2015 Sep 10;162(6):1309-21. (PMID: 26343579)
BMC Neurosci. 2019 Apr 25;20(1):18. (PMID: 31023212)
Int J Mol Sci. 2024 Mar 31;25(7):. (PMID: 38612737)
Parkinsons Dis. 2011;2011:327089. (PMID: 21603177)
Shock. 2018 Apr;49(4):474-482. (PMID: 28682942)
Occup Environ Med. 2003 May;60(5):378. (PMID: 12709528)
Eur J Pharm Biopharm. 2022 Nov;180:289-307. (PMID: 36272656)
Int Immunopharmacol. 2022 Oct;111:109127. (PMID: 35964407)
Cancer Lett. 2020 Jan 28;469:102-110. (PMID: 31666180)
J Immunol. 2016 Sep 15;197(6):2390-9. (PMID: 27534554)
BMC Cancer. 2013 Feb 26;13:91. (PMID: 23442743)
Prostate. 2019 Feb;79(2):168-182. (PMID: 30264470)
Brain Behav Immun. 2013 Jan;27(1):91-100. (PMID: 23044176)
PLoS One. 2013 Apr 09;8(4):e61057. (PMID: 23585870)
Front Cell Infect Microbiol. 2024 May 07;14:1374238. (PMID: 38774627)
Med Microbiol Immunol. 2024 May 20;213(1):8. (PMID: 38767707)
Infect Agent Cancer. 2016 Mar 03;11:12. (PMID: 26941832)
Int J Mol Sci. 2018 Oct 22;19(10):. (PMID: 30360353)
PLoS One. 2018 Jan 17;13(1):e0189721. (PMID: 29342165)
J Biol Regul Homeost Agents. 2021 Mar 10;35(2):495-504. (PMID: 33687909)
Cancer Cell Int. 2023 Apr 10;23(1):64. (PMID: 37038154)
Anticancer Res. 2012 Oct;32(10):4331-7. (PMID: 23060555)
J Bacteriol. 2006 Apr;188(7):2735-9. (PMID: 16547065)
PLoS Pathog. 2009 Sep;5(9):e1000567. (PMID: 19730692)
Cell Commun Signal. 2024 Apr 24;22(1):239. (PMID: 38654309)
BMC Microbiol. 2020 Nov 17;20(1):353. (PMID: 33203384)
J Neurol. 2008 Feb;255(2):265-72. (PMID: 18283402)
Am J Pathol. 2015 Sep;185(9):2390-401. (PMID: 26212908)
Microbiology (Reading). 2023 Jun;169(6):. (PMID: 37279149)
Oncotarget. 2017 May 30;8(22):36492-36508. (PMID: 28445131)
J Cereb Blood Flow Metab. 2009 May;29(5):921-32. (PMID: 19240744)
Pathogens. 2021 Oct 09;10(10):. (PMID: 34684248)
J Alzheimers Dis. 2016 Jun 18;53(4):1237-56. (PMID: 27340854)
Gut. 2019 May;68(5):829-843. (PMID: 30554160)
Front Cell Infect Microbiol. 2024 Feb 29;14:1347813. (PMID: 38487353)
J Clin Oncol. 2002 Jan 1;20(1):142-52. (PMID: 11773163)
Mol Aspects Med. 2021 Oct;81:100997. (PMID: 34311996)
J Korean Med Sci. 2012 Sep;27(9):1062-5. (PMID: 22969253)
Int J Mol Sci. 2023 Jul 25;24(15):. (PMID: 37569283)
Cancer Res. 1991 May 15;51(10):2524-30. (PMID: 2021932)
Int J Mol Sci. 2017 Sep 22;18(10):. (PMID: 28937602)
Clin Chem. 2003 Jul;49(7):1149-53. (PMID: 12816912)
Int Immunopharmacol. 2022 Oct;111:109022. (PMID: 35987146)
Eur J Cancer. 1996 Sep;32A(10):1712-8. (PMID: 8983279)
J Mol Neurosci. 2021 Aug;71(8):1556-1566. (PMID: 31939106)
Diagnostics (Basel). 2022 Dec 27;13(1):. (PMID: 36611371)
Front Immunol. 2016 Nov 04;7:484. (PMID: 27867387)
Microorganisms. 2023 Jan 19;11(2):. (PMID: 36838231)
Cell. 2020 Jan 9;180(1):33-49.e22. (PMID: 31813624)
Front Immunol. 2020 Apr 17;11:686. (PMID: 32362899)
Microorganisms. 2020 Sep 24;8(10):. (PMID: 32987719)
J Immunother. 2020 Sep;43(7):217-221. (PMID: 32554977)
PLoS Pathog. 2021 Apr 30;17(4):e1009550. (PMID: 33930101)
J Neuroinflammation. 2015 Feb 03;12:20. (PMID: 25644393)
Int J Biol Macromol. 2019 Dec 1;141:1228-1245. (PMID: 31520703)
Cell Host Microbe. 2015 Jun 10;17(6):763-74. (PMID: 26028364)
J Immunol. 2001 Nov 1;167(9):5067-76. (PMID: 11673516)
Adv Drug Deliv Rev. 2022 Jun;185:114295. (PMID: 35429576)
Front Immunol. 2023 May 08;14:1066402. (PMID: 37223101)
Int J Mol Sci. 2018 Aug 28;19(9):. (PMID: 30154361)
Front Cell Infect Microbiol. 2017 Jul 11;7:318. (PMID: 28744452)
Folia Morphol (Warsz). 2017;76(4):596-602. (PMID: 28394007)
Brain Behav Immun Health. 2020 Mar 18;4:100060. (PMID: 34589845)
Cell Rep. 2021 Sep 14;36(11):109691. (PMID: 34525353)
Microorganisms. 2020 Mar 13;8(3):. (PMID: 32183199)
Microbiol Res. 2020 Sep;238:126502. (PMID: 32535400)
Neurochem Int. 2015 Aug;87:92-105. (PMID: 26055970)
J Am Vet Med Assoc. 2022 Nov 24;261(3):1-6. (PMID: 36434765)
Mol Ther. 2022 Feb 2;30(2):662-671. (PMID: 34400328)
J Neurosci. 2004 Feb 11;24(6):1340-9. (PMID: 14960605)
Pharmaceutics. 2023 Jul 21;15(7):. (PMID: 37514190)
Gut Pathog. 2017 Dec 12;9:73. (PMID: 29255488)
J Neuroinflammation. 2015 Nov 25;12:223. (PMID: 26608623)
Obes Facts. 2016;9(1):1-11. (PMID: 26745497)
Brain Behav Immun. 2010 Jan;24(1):102-9. (PMID: 19735725)
BMC Vet Res. 2024 Aug 10;20(1):358. (PMID: 39127648)
BMC Neurosci. 2009 Nov 18;10:135. (PMID: 19922669)
Shock. 2020 Feb;53(2):171-174. (PMID: 31008870)

1111 University of Warmia and Mazury in Olsztyn

Keywords: LPS; Salmonella; asymptomatic LPS; asymptomatic carrier state; biosafety; cancer; oncogenic and oncolytic Salmonella; serotype diverse activity; unknown long-term consequences

0 (Lipopolysaccharides)

Date Created: 20241127 Date Completed: 20241127 Latest Revision: 20241205

20241209

PMC11593640

10.3390/ijms252211868

39595937